Human Immunoglobulin G may now be used with insurance benefits for the treatment of thrombosis thrombocytopenia syndrome (TTS), a known adverse event following COVID-19 vaccinations.

Expansion of benefit standards for general drugs usually takes around 80 days, however, due to the specificity of the COVID-19 situation, the reimbursement standard was expanded in a single day.

The Health Insurance Review and Assessment Service announced on the 1st that it has secured a safety net for the public against side effects that arise post-vaccination by reviewing the health insurance benefit standards in the shortest period ever.

TTS is a rare condition, and only two TTS cases were